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Abstract
Background: Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD)
trials; the placebo response of devices such as repetitive transcranial magnetic stimulation (rTMS) has not been
systematically assessed. We proposed to assess placebo responses in two categories of MDD trials: pharmacological
(antidepressant drugs) and non-pharmacological (device- rTMS) trials.
Methodology/Principal Findings: We performed a systematic review and meta-analysis of the literature from April 2002 to
April 2008, searching MEDLINE, Cochrane, Scielo and CRISP electronic databases and reference lists from retrieved studies
and conference abstracts. We used the keywords placebo and depression and escitalopram for pharmacological studies;
and transcranial magnetic stimulation and depression and sham for non-pharmacological studies. All randomized, double-
blinded, placebo-controlled, parallel articles on major depressive disorder were included. Forty-one studies met our
inclusion criteria - 29 in the rTMS arm and 12 in the escitalopram arm. We extracted the mean and standard values of
depression scores in the placebo group of each study. Then, we calculated the pooled effect size for escitalopram and rTMS
arm separately, using Cohen’s d as the measure of effect size. We found that placebo response are large for both
escitalopram (Cohen’s d - random-effects model - 1.48; 95%C.I. 1.26 to 1.6) and rTMS studies (0.82; 95%C.I. 0.63 to 1).
Exploratory analyses show that sham response is associated with refractoriness and with the use of rTMS as an add-on
therapy, but not with age, gender and sham method utilized.
Conclusions/Significance: We confirmed that placebo response in MDD is large regardless of the intervention and is
associated with depression refractoriness and treatment combination (add-on rTMS studies). The magnitude of the placebo
response seems to be related with study population and study design rather than the intervention itself.
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Introduction
Placebo effect plays a significant role in clinical trials of major
depressive disorder (MDD); in fact, two recent meta-analyses
showed that the mean responder raters in the placebo group in
antidepressant trials are 29.7% [1] and that drug-placebo
differences might be relatively small in patients with MDD due
to the large placebo response [2]. Given the importance of placebo
response in MDD trials and the need to develop efficient research
designs, it is critical to enhance our understanding on the placebo
effects of distinct treatments such as repetitive transcranial
magnetic stimulation (rTMS), a novel non-pharmacological
intervention for neuropsychiatric diseases.
Several meta-analyses of rTMS clinical trials have been
performed in the past ten years, initially showing negative or poor
results [3,4]; although two recent studies have demonstrated a
greater efficacy of the method [5,6]. However, taking into account
the heterogeneity of rTMS trialsand the lack ofprecisepredictorsof
outcome, Herrmann and Ebmeier [7] proposed that non-specific
contextual effects - such as the use of a new and relatively unknown
technological device and the running of trials in major universities
and teaching hospitals - play an important role in rTMS depression
improvement. In fact, non-pharmacological treatments might have
a large placebo response [8]. Furthermore, despite several meta-
analyses assessing the placebo response of pharmacological trials in
depression [1,2,9,10] placebo response of transcranial magnetic
stimulation has not been sufficiently explored. We therefore decided
to assess the placebo response of such intervention and perform an
exploratory comparison with a non-pharmacological intervention
trough a systematic review and meta-analysis of recent clinical trials
of major depression.
Aims of the study
This study sought to ascertain the magnitude of placebo
response in controlled trials of rTMS and non-pharmacological
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4824studies using escitalopram as the antidepressant drug. Our
secondary aim, given the limitations for such aim, was to
exploratory compare the effect sizes of placebo responses of
rTMS studies and pharmacological studies. The importance of our
study is contribute towards a better understanding of the placebo
effects mechanisms by comparing a traditional pill-taking medical
ritual to a new sham-device healing context.
Methods
We chose escitalopram to estimate the placebo response of
pharmacological treatment as several placebo-controlled trials
have been recently conducted and for non-pharmacological
treatment we chose rTMS as, similarly, several sham-controlled
studies have also been performed recently. We performed a
systematic review on all escitalopram and rTMS trials published
since 2002 and subsequently performed two main analyses: for the
placebo-drug response and for the sham-rTMS response. We then
compared the effect size of these groups. We also performed
exploratory analyses to assess predictors associated with placebo
response.
We choose this time period because the first escitalopram trial
was published in 2002 and we looked for concurrent rTMS and
escitalopram trials to make the studies more comparable
methodologically (i.e., with comparable sample sizes, diagnostic
definitions, rating methods and quality of studies) and also because
a meta-analysis performed in 2003 [3] stated that rTMS trials up
to 2002 had been of low quality.
Literature Search
We searched for published articles from April 2002 to April
2008 (period of 96 months) in the following databases: MEDLINE,
Web of Science, Cochrane, and SCIELO. We also examined
reference lists in systematic reviews and retrieved papers. To check
for unpublished trials, we: (i) consulted the CRISP database and
the websites clinicaltrials.gov and clinicalstudyresults.org; (ii)
contacted experts; (iii) searched for conference poster abstracts;
(iv) searched for studies in the monograph reference lists of
Lexapro H and; (iv) sent e-mails asking for unpublished studies to
Forest Labs and to Lundbeck S/A. Our key search terms were
‘‘depression’’, ‘‘escitalopram’’, and ‘‘placebo’’ in the escitalopram
arm; and ‘‘depression’’, ‘‘transcranial magnetic stimulation’’ and
‘‘sham’’ in the rTMS arm.
Selection criteria
The following inclusion criteria were adopted: (i) manuscript
written in English (although there were no manuscripts in other
languages); (ii) randomized, double-blinded, placebo-controlled (or
sham-controlled), parallel studies on major depressive disorder; (iii)
mood effects assessed by a continuous mood scale, such as
Hamilton Depression Rating Scale (HDRS) or Montgomery-
Asberg Depression Rating Scale (MADRS); (iv) studies that
reported mean and standard deviation of the mood scales (or
provided other statistical parameters that could be used to deduce
this values) for the placebo group and; (v) studies published from
April 2002 to April 2008.
Data extraction
Data were extracted independently by the first author (AB) and
double-checked by the second author (ML), using a structured
form. The discrepancies were resolved by consensus and the
corresponding author (FF) consulted if needed. The following
variables were extracted: 1) mean and standard deviation values of
depression rating scales at baseline and end of treatment in active
(active group was used for exploratory analysis) and placebo/sham
groups and; 2) demographic, clinical and treatment characteristics
(e.g. number of patients, age, gender, previous use of medications,
depression-resistant subjects, duration of treatment, sham proce-
dure utilized).
When the study did not report mean and standard deviation
(SD) values, we either deduced them (using statistical parameters)
or contacted the corresponding author. Many escitalopram studies
did not report SD final scores – in these cases, we calculated SD
from standard error (SE) at end-of-treatment or from SD or SE
difference changes when possible [11,12]. In two studies, SD had
been only reported in graphs and we asked for data from Forest
Research Institute [13,14]. We also received data from Forest
Labs of two posters [15,16] and for an unpublished trial
mentioned in another study [13]. Two authors failed to provide
the requested data [17,18]; in these cases we had to input SD post-
treatment scores based on the mean of the available SD scores of
other trials, a method suggested by The Cochrane Collaboration
to be applied in such cases [19]. In the rTMS arm, some trials just
reported data in graphs, while others did not report SD post-
treatment scores. We contacted the corresponding authors in these
cases [20,21,22,23]. Many rTMS trials also reported several
depression scores at different times using more than one
depression scale -in such cases, we extracted the data presented
by the authors as the main result. Finally, we used only unadjusted
rating scores in our analysis.
Quality assessment
We looked for the following biases: (1) selection bias - adequate
concealment of treatment (e.g., randomization was performed by
lottery and sealed, opaque envelopes were used); (2) performance
bias – if the study is single-blinded or double-blinded - for rTMS
studies we checked if they were single-blinded studies with external
blind raters and also if blinding of patients and physicians were
assessed; (3) attrition bias – if data are adequately reported in the
study, if there is evidence of intention-to-treat treatment, and if
methods used to handle with missing data (e.g., last observation
carried forward, complete case analysis) were reported.
Quantitative analysis
All of our analyses were performed using STATA statistical
software, version 9.0 (Statacorp, College Station, TX, USA). We
initially calculated the standardized mean difference and the
pooled standard deviation for each comparison –i.e. for each study
we calculated the change of either placebo or sham scores (baseline
minus post-treatment scores) and divided by the standard
deviation of change. We used Cohen’s d as a measure of the
effect size. Then, we measured the pooled weighted effect size
(weighted by the inverse variance of each study) using the random
and fixed effect models. We performed the analyses of placebo
response in escitalopram and rTMS trials separately and further
compared the pooled effect sizes. Heterogeneity was evaluated
with Chi-square test. We also performed sensitivity analysis,
cumulative regression and assessed publication bias using Begg-
modified funnel plot and Egger test [24] for each analysis.
Meta-regression was performed using the random-effects model
and tau
2 variance was calculated by the method of the residual
maximum likelihood. We tested the following variables: age
(years), gender (%females), duration of treatment (weeks), and
depression response in the active groups (Cohen’s d pooled effect
size of the active groups) – treated as continuous variables; sham
procedure, treatment resistant patients (defined as more than 50%
of patients failed at last two antidepressant treatments); drug-free
patients; and rTMS as an add-on therapy were treated as categorical
Placebo Response in Depression
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coil’’ studies that described the use of an active rTMS coil in a
different angle or position when applied to the scalp; whereas
‘‘sham coil’’ included studies that used a non-active coil associated
with a method to preserve blindness (e.g. a study [25] described
that sham stimulation was performed with ‘‘an identical coil (…)
but without any electronic connection. This set-up had a similar
sound effect but with no stimulation…’’). Three studies used a
different sham approach and were not pooled together in this
analysis, because either a shielded coil [26] or a special coil
generating a small field [23] were used.
Also, we considered as ‘‘add-on therapy’’ when a drug treatment
was initiated simultaneously to active or sham rTMS, i.e., patients
from sham group were actually starting an active drug treatment -in
fact, this is the same concept of an ‘‘accelerating’’ study [27].
For baseline depression, we meta-regressed using either MADRS
or HDRS baseline scores in escitalopram and rTMS trials,
respectively. For rTMS studies that used MADRS scores as the
primary outcome, we used the values of HDRS scores reported in
secondary outcomes when this was possible [26,28,29,30,31]; in four
studies this was not possible [20,32,33,34] and therefore we imputed
missing HDRS scores regressing for other variables. Finally we
assessed whether improvement in the active group was correlated
with the placebo response – including this variable in our model.
Results
Using the keywords previously mentioned we were able to find
67 citations for escitalopram and 92 for rTMS studies. Only 12
and 29 studies met our inclusion criteria. Reasons for exclusion
included: (1) reviews and meta-analyses; (2) studies that assessed
other psychiatric diseases; (3) other studies designs (open-label,
cross-over designs, quasi-randomized trials); (4) lack of sham or
placebo group; (5) other topics. (Fig. 1)
Regarding study quality, all escitalopram studies are multi-
centric, randomized (although only one study reports the
allocation method), double-blinded, and performed an intention-
to-treat analysis (ITT), using the last observation carrier forward
(LOCF) method. The quality of the rTMS studies is heteroge-
neous: all studies are randomized (thirteen studies report the
allocation method); and single-blinded with external evaluation
but only 8 studies addressed the integrity of blinding. Eighteen
studies performed an intention-to-treat analysis, while 11 per-
formed a complete-case analysis – mostly, exploratory studies.
Finally, only two rTMS studies are multicentric. The quality
assessment of each study is reported in Table S1.
The clinical characteristics of the 41 studies are summarized in
Table 1. Tables 2 and 3 show characteristics of each study. There
were 680 patients in sham group in the 29 rTMS studies (median
per study=16, interquartile range (IQR)=10–26), while the 12
escitalopram studies enrolled 1714 patients in the placebo group
(median per study=133, IQR=128–153). Also, all escitalopram
studies enrolled non-treatment resistant patients who were drug-
free, while most patients in rTMS studies were refractory and
using antidepressant drugs – in fact, in 6 studies an antidepressant
drug was initiated in both active and sham groups at the beginning
of the trial. Conversely, the groups were comparable regarding age
(50.7 vs. 43.1 years), gender (59% vs. 61% females) and baseline
HDRS (24.73 vs. 21.4) and MADRS (33.1 vs. 29.23) scores.
Our main results show that the pooled effect sizes for placebo
response in escitalopram trials are 1.46 (95% CI 1.38 to 1.53)
Figure 1. QUOROM flow chart used to identify studies for detailed analysis.
doi:10.1371/journal.pone.0004824.g001
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the random-effects model; and, for rTMS studies, the sham pooled
effect size is, in the fixed-effects model, 0.77 (95% CI 0.66 to 0.88)
and 0.82 (95% CI 0.63 to 1) in the random-effects model (Fig. 2).
Since heterogeneity is significant in both analyses (x2=86.54,
p,0.001 and x2=66.87, p,0.001, respectively) subsequent
analyses were performed using the random-effects model. For
both arms, sensitivity analysis and Begg’s funnel plot show neither
change in results after the exclusion of any particular study nor
evidence of publication bias and systematic heterogeneity across
the studies (Figures S1 and S2).
Subgroup analyses also show that the sham effect size of add-on
rTMS studies (1.47, 95% CI 1.24–1.70) differ from studies not
adopting such strategy (0.56, 95% CI 0.44–0.7, p,0.001), and of
non-refractoriness studies (1.24, 95% CI 0.96–1.52) vs. studies
with treatment-resistant patients (0.55, 95% CI 0.42 to 0.68,
p,0.001) (Figure S3).
Exploratory analysis
Simple linear regressions (table 4) show that some variables are
associated with the outcome: (1) a negative association is observed
for treatment resistant patients (ß coefficient=20.69, p,0.001),
meaning that refractoriness diminish placebo response; (2) a
positive association (ß coefficient=0.9, p,0.001) is observed for
rTMS as add-on therapy, meaning that placebo response increases
in accelerating studies and; (3) a positive association is observed for
depression improvement in active groups for both escitalopram
(B=0.7, p,0.0001) and rTMS studies (B=0.33, p=0.002), i.e.,
studies showing a large depression improvement in active group
also showed a large depression improvement in the control group.
On the contrary, baseline HDRS scores, baseline MADRS
scores, depression scale utilized, gender and age are not associated
with placebo response for both escitalopram and rTMS studies -
except for baseline HDRS scores in rTMS studies (B=0.52,
p=0.04), i.e., depression severity associates with a large placebo
response.
Finally, variables that were associated with the outcome (p,0.1)
were included in multiple linear regressions (Table 5). We observe
that in models 1a (covariates: active-rTMS treatment and add-on
therapy) and 1b (covariates: HDRS baseline scores and add-on therapy)
only rTMS as add-on therapy remains associated with the outcome.
Similarly, the variable baseline HDRS scores looses significance when
meta-regressed together with treatment resistant (model 2b); however,
in model 2a, both depression improvement in active-rTMS group (B=0.2,
p=0.02) and treatment resistant (B=20.57, p,0.0001) associates
with placebo response. In model 3 all mentioned variables are
regressed together; results show that only rTMS as add-on therapy
still positively associates with the outcome (B=0.53, p=0.02),
although there is still a trend for a negative association for treatment
resistant variable (B=20.31, p=0.08), meaning that such variables
still modify placebo response even when controlled by other
significant variables.
Discussion
This meta-analysis includes data from 12 escitalopram and 29
rTMS trials, assessing 2394 subjects in placebo/sham groups. Our
main result shows that placebo response is large in major
depression trials, regardless of the placebo method. Exploratory
analyses found that patients with severe depression and with
treatment-resistant depression present a lower placebo response;
while in trials that rTMS is initiated concomitantly with an
antidepressant drug, the placebo response is larger.
The main finding of our study is that both placebo interventions
are associated with a large effect size in major depressive disorder,
which is in line with previous studies: Walsh et al. [1] reviewed 75
depression trials and concluded that placebo response is
substantial and increasing over years; Stein et al. [35] in a pooled
analysis of five escitalopram trials showed that placebo response
ranged from 31.6% to 45.9%; and Kirsch et al [2], reviewing 35
published and unpublished trials, showed that placebo response
ranged from 0.7 to 1.1 Cohen’s d. Therefore our study confirms
that placebo response is substantial in pharmacological and non-
pharmacological trials in major depression.
Another finding of our study is that placebo-drug response
appears to be larger than sham-rTMS response – even controlling
for treatment refractoriness. Even considering that the small
difference might not be meaningful, this finding is contrary to
conventional wisdom that sham devices would have a higher
Table 1. General characteristics of the studies.
rTMS Escitalopram
Number of studies 29 12
Patients in active group 715 1967
Patients in sham/placebo group 680 1714
Age (mean6SD) * 50.76 (7.56) 43.1 (16.6)
Gender (%female) * 59% 61%
Refractory to Antidepressants (%) 73% 0
Concomitant antidepressant use in placebo group(%) 76% 0
Studies that used HDRS in the primary outcome 20 3
HDRS baseline scores (mean6SD) * 24.73 (4.47) 21.4 (3.20)
HDRS post-treatment scores (mean6SD) * 19.78 (3.57) 11.4 (0.3)
Studies that used MADRS in the primary outcome 9 8
MADRS baseline scores (mean6SD) * 33.1 (3.59) 29.23 (0.90)
MADRS post-treatment scores (mean6SD) * 26.2 (6.25) 17.72 (1.96)
SD=standard deviation; MADRS=Montgomery-Asberg Depression Rating Scale; HDRS=Hamilton Depression Rating Scale; rTMS=repetitive transcranial magnetic
stimulation. (*) In sham/placebo group.
doi:10.1371/journal.pone.0004824.t001
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intervention showed increased response than a placebo pill in a
prospective sham device vs. inert pill trial [37] and in a meta-
analysis comparing subcutaneous placebo with oral placebo from
acute migraine [38]. Our finding does however agree with a
smaller acute care study that found no difference between
parenteral medication and oral medication [39]. These differences
could be related to the concept that placebo response is very
heterogeneous and influenced by many variables. In our study, this
finding might be explained by several factors:
(1) Study populations are different: 73% of rTMS trials enrolled
refractory MDD patients; whereas no escitalopram trials
enrolled refractory patients – in fact, STAR*D (Sequenced
Treatment Alternatives to Relieve Depression) trial shows that
remission rates decay at each time an antidepressant drug fail,
being only 13% for refractory patients – i.e. patients who
failed to remit after two trials [40]; and, since antidepressant
drug effect is partially composed by a non-specific, placebo
effect, placebo response might also decay in refractory
patients. Along with these lines, low placebo responses were
reported in a recent rTMS meta-analysis that addressed
treatment-resistant patients [41] as well as two drug meta-
analyses using lithium [42] and atypical antipsychotics [43].
(2) Study designs are different: although escitalopram and rTMS
trials present comparable quality, they mainly differ in
blinding quality, as adequate blinding is more difficult to
obtain in non-pharmacological interventions [44]. The rTMS
trials assessed used an approach in which patients and raters
were blinded to the treatment group allocated; however, it is
possible that rTMS appliers unconsciously behave different
when applying real and sham stimulation as well as that
patients discover in which intervention they were allocated.
Unsuccessful blinding biases the results as expectation effects
and intervention confidence will be lost [45,46,47,48],
therefore diminishing placebo response. Also, it is possible
Table 2. Characteristics of each rTMS study included.
Author and Year
Patients in
sham
group
Age
(mean)
No f
female
Depression
scale
Baseline
sham
scores
Post-tto
sham
scores
Add-on
therapy
Treatment
resistant
Concomitant
AD use
Boutros [57] 9 49.5 1 HDRS 35.44 26.42 No Yes Yes
Hoppner [28] 9 56 6 MADRS 37.5 29 No No Yes
Fitzgerald [32] 20 49.15 11 MADRS 35.75 35.4 No Yes Yes
Loo [33] 10 54.9 6 MADRS 33.1 27 No Yes Yes
Herwig [21] 12 47.8 8 HDRS 23.1 14.5 No Yes Yes
Koerselman [58] 26 52 17 HDRS 25.9 20.2 No No Yes
Poulet [20] 9 N/A 4 MADRS 36.22 18.125 Yes No Yes
Holtzheimer [59] 7 45.4 4 HDRS 20.8 15.3 No Yes No
Jorge [60] 10 66.5 5 HDRS 20.8 20 No Yes No
Mosimann [61] 9 64.4 5 HDRS 24.5 20.4 No Yes Yes
Hausmann [62] 13 47 9 HDRS 33.7 20.2 Yes N/A Yes
Rossini (J Clin Psych)
[63]
49 46.4 40 HDRS 25.1 16.8 Yes No Yes
Rumi [64] 24 38.9 20 HDRS 29.71 22.1 Yes No Yes
Rossini (Psych Res), [22] 17 56.3 11 HDRS 28.7 24.9 No Yes Yes
Su [65] 10 42.6 7 HDRS 22.7 19 No Yes Yes
Januel [66] 16 37.19 12 HDRS 22.5 16.69 No No No
Fitzgerald [31] 27 43.7 16 MADRS 34 30.9 No Yes Yes
Avery [67] 33 44.2 16 HDRS 23.5 20 No Yes Yes
Garcia-Toro [68] 10 47.2 7 HDRS 25.1 23.67 No Yes Yes
Loo [29] 19 45.7 8 MADRS 32.6 27.1 No No Yes
Herwig [30] 65 49 32 MADRS 27.1 16.3 Yes No Yes
O’Reardon [26] 146 48.7 74 MADRS 33.9 30 No Yes No
Anderson [34] 16 48 9 MADRS 27.7 21.9 No Yes Yes
Stern [69] 10 53.3 6 HDRS 27.4 26.7 No Yes Yes
Bortolomasi [70] 7 55.6 4 HDRS 22 19 No Yes Yes
Jorge1 [23] 15 66.1 8 HDRS 19.9 16.8 No Yes No
Jorge2 [23] 29 62.1 17 HDRS 17.6 14.8 No Yes No
Mogg [71] 30 52 21 HDRS 21.6 19.4 No Yes Yes
Bretlau [25] 23 57.8 13 HDRS 24.7 19.1 Yes Yes Yes
rTMS=repetitive transcranial magnetic stimulation; AD=antidepressant drug; HDRS=Hamilton Depression Rating Scale; MADRS=Montgomory-Asberg Depression
Rating Scale; N/A=data not available.
doi:10.1371/journal.pone.0004824.t002
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Author and Year
Patients in
placebo group
Age
(mean)
No f
female
Depression
scale
Baseline
placebo
scores
Post-tto
placebo
scores
Weeks of
treatment
Treatment
resistant
Burke [11] 119 40 71 MADRS 29.5 20.1 8 No
Wade [72] 189 40 147 MADRS 28.7 16.7 8 No
Lepola [73] 154 43 111 MADRS 28.7 16.2 8 No
Ninan [15] 153 39 99 MADRS 30.5 20.5 8 No
Rapaport { [13] 127 42.2 74 MADRS 28.8 17.5 8 No
Alexopoulos [16] 132 N/A 75 MADRS 30.7 18.4 8 No
Kasper [17] 180 75 137 MADRS 28.6 14.6 8 No
Clayton2 [12] 126 37 73 HDRS 23.3 11.4 8 No
Clayton1 [12] 130 35 81 HDRS 23.2 11.1 8 No
Wagner [74] 133 12.4 69 CDRS 56.6 36.4 8 No
Nierenberg [18] 137 42.5 49 HDRS 17.7 11.7 8 No
Bose [14] 134 68.5 79 MADRS 28.4 17.8 12 No
{Data of unpublished study. HDRS=Hamilton Depression Rating Scale; MADRS=Montgomory-Asberg Depression Rating Scale; CDRS=Children’s Depression Rating
Scale; N/A=data not available.
doi:10.1371/journal.pone.0004824.t003
Figure 2. Forest plots showing placebo response in control groups of escitalopram (A) and rTMS (B) studies. Forest plots show effect
sizes from the random effects model. A negative effect indicates that endpoint depression scores in control groups are higher than baseline scores.
Effect sizes are Cohen’s d (standardized mean difference), error bars represent the 95% confidence interval.
doi:10.1371/journal.pone.0004824.g002
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showed that, in schizophrenia controlled-trials, improvement
was larger in trials having no placebo arm; and Trivedi et al.
[50] showed that response raters were different in depression
controlled-trials regarding using or not a placebo run-in
phase.
(3) Study sites and approaches are different: whereas drug trials
are conducted along 8 weeks, with weekly returns, rTMS trials
are conducted in 2 to 4 weeks – therefore longer exposure
might be associated with a larger placebo response. On the
other hand, rTMS treatment is associated with an intensive
10-day treatment (as opposed to weekly or bi-weekly
interaction in drug trials) and this could potentiate placebo
response in the rTMS trials.
Our results show that sham-response is smaller in trials that
rTMS is not used as add-on therapy (0.56 vs. 1.24), suggesting that
such device might not be associated with a large placebo effect, a
finding that was also observed in meta-analyses of Parkinson’s
disease [51] and of refractory MDD [41]. Also, add-on rTMS
trials improve response in placebo arm even when controlled for
other variables, which could point to a synergistic effect between
sham-rTMS and the drug, since there is no association between
placebo response and previous use of antidepressant drugs. Finally,
sham method (sham coil vs. angled coil) does not change placebo
response – perhaps because both approaches, in fact, do not
guarantee blinding.
Limitations
There was significant between-study heterogeneity in our meta-
analysis, suggesting that the variation of effect size estimates in the
studies were more than expected by chance. To address this
limitation, we (1) used a random-effects model, which is a more
conservative pooled analysis that take into account the between-
study heterogeneity; (2) performed sensitivity analyses, to address
whether the exclusion of an study could affect the pooled effect
size; (3) assessed the quality of each study, looking for potential
biases; and (4) checked for publication biases using Begg’s funnel
plot.
Another limitation is that, for pharmacological studies, we only
included escitalopram studies; consequently, it is possible that the
placebo response of other drugs is different. However, our study is
in line with previous meta-analyses that showed similar placebo
responses in major depression studies [1,52], assessed a significant
number (1714) of patients and included unpublished studies;
therefore this hypothesis is less likely.
Finally, it should be emphasized that the secondary analyses
performed are exploratory and might be underpowered; in fact,
since ten linear regressions have been performed in each pooled
analysis, there is a 50% probability of observing one positive
association merely due to chance.
Table 4. Meta regression results in which several variables were analyzed trough simple linear regressions.
Explanatory variables Escitalopram rTMS
d.f. Coef. (B) p d.f. Coef. (B) p
Baseline MADRS/HDRS 6 20.12 0.23 27 0.52 0.04
Depression scale (HDRS vs MADRS) 10 20.15 0.40 27 0.05 0.79
Gender (n Female) 10 ,0.001 0.09 27 ,0.001 0.96
Age (years) 9 0.07 0.36 26 20.2 0.14
Patients using ADs (Y/N) - - - 27 0.21 0.36
Tto Resistant (Y/N) (*) 26 20.69 ,0.0001
Week of post-tto scores (**) 27 20.03 0.56
Sham method (Coil angled vs. Sham coil) - - - 24 20.21 0.35
rTMS as add-on therapy (Y/N) - - - 27 0.90 ,0.0001
Active Group change (Cohen’s d) 10 0.70 ,0.0001 27 0.33 0.002
Coef. (B) is the regression coefficient of each regression, representing the slope of each model. Significant observations (p,0.05) are highlighted in bold. D.f.=degrees
of freedom; HDRS=Hamilton Depression Rating Scale; rTMS=repetitive transcranial magnetic stimulation; AD=antidepressant drug; MADRS=Montgomery-Asberg
Depression Rating Scale; MDD=Major Depressive Disorder; Y/N=yes or no. (*) There are no escitalopram studies that enrolled patients with refractory MDD. (**) All
escitalopram studies except one assessed post-treatment scores at week 8.
doi:10.1371/journal.pone.0004824.t004
Table 5. Exploratory regression models for rTMS studies in
which significant results (obtained from simple linear
regressions) were forced into several models.
Regression
model Variable D.f. Coef (B) p
Model 1a Active rTMS Group improvement 26 0.12 0.14
rTMS as add-on Therapy 0.77 ,0.0001
Model 1b Baseline HDRS scores 26 0.15 0.45
rTMS as add-on Therapy 0.86 ,0.0001
Model 2a Treatment resistant 26 20.57 ,0.0001
Active rTMS Group improvement 0.20 0.02
Model 2b Baseline HDRS scores 25 0.03 0.25
Treatment resistant 20.49 ,0.0001
Model 3 Baseline HDRS scores 23 0.01 0.86
Treatment resistant 20.31 0.08
Active rTMS Group improvement 0.11 0.21
rTMS as add-on Therapy 0.53 0.02
Coef. (B) is the regression coefficient of each regression, representing the slope
of each model. Significant observations (p,0.05) are highlighted in bold.
D.f.=degrees of freedom; HDRS=Hamilton Depression Rating Scale;
rTMS=repetitive transcranial magnetic stimulation.
doi:10.1371/journal.pone.0004824.t005
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Because we addressed the influence of several variables in sham-
response, our results have some implications for future rTMS trial
designs, such as: (1) sham device method is not associated with
placebo response; therefore this factor seems less relevant than
currently considered by the researchers in this field [53]; (2) age
and gender are probably not related with placebo response -
although age seems to be related to depression response in some
studies [54,55]; (3) refractoriness is associated with a lower placebo
response – and, in fact, a lower depression response [41,54] [56];
perhaps indicating that such patients are very unresponsive to any
intervention at all and therefore rTMS studies should focus on
non-refractory patients or, on the contrary, the positive results of
rTMS trials might be due to a lower placebo response that
increases active-sham difference – therefore, future rTMS trials
should quantify the degree of refractoriness of each patient, and;
(4) placebo response is high in add-on rTMS trials – this could
indicate there is a synergistic effect with the drug and, therefore,
future trials could use a two-way factorial design (i.e., sham vs.
real-rTMS and placebo vs. active drug) to address the relationship
among rTMS and drug interventions.
Our study also stresses the heterogeneity of placebo response in
different contexts and interventions; therefore, the lower placebo
response observed in sham trials could be explored by using a
qualitative approach to understand patient’s expectancies regard-
ing rTMS intervention or, perhaps, by a sham-device vs. inert pill
trial, in the same fashion of a prior placebo study [37].
Final remarks
In summary, our study shows that placebo response in rTMS
and escitalopram trials is large and appears to be lower for rTMS
trials. The sham response is negatively associated with refracto-
riness and positively associated with rTMS add-on studies;
whereas sham method utilized, age and gender are not associated
with a greater sham response. It is possible that design issues such
as the lack of adequate blinding associate with lower placebo
responses; however, we cannot measure in which extent such
difference is explained by other cultural factors, as pill-taking
healing is a mainstream medical ritual, while sham devices are not.
The sham response of rTMS significantly varies among studies
and can influence the results of a clinical trial as it will determine
the effect size of a given sham-controlled trial, therefore, further
studies are needed to explore its effects as to design appropriate
sham-controlled randomized clinical trials.
Supporting Information
Table S1 The file contains the quality assessment of all the
studies included.
Found at: doi:10.1371/journal.pone.0004824.s001 (0.57 MB PPT)
Figure S1 (A) shows the sensitivity analysis, assessing the
individual influence of a particular study by showing the resulting
effect size and 95% confidence interval (CI) after its exclusion. (B)
shows the funnel plot of the effect sizes (Cohen’s d) according to
their standard errors. Cohen’s d is the standardized mean
difference, error bars represent the 95% CI.
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Figure S2 (A) shows the sensitivity analysis, assessing the
individual influence of a particular study by showing the resulting
effect size and 95% confidence interval (CI) after its exclusion. (B)
shows the funnel plot of the effect sizes (Cohen’s d) according to
their standard errors. Cohen’s d is the standardized mean
difference, error bars represent the 95% CI.
Found at: doi:10.1371/journal.pone.0004824.s003 (3.00 MB TIF)
Figure S3 (A) shows the influence of the variable add-on rTMS
in the pooled analysis of the studies, by pooling together only
studies in which this variable is present (top) or absent (bottom)
and thereby comparing the resulting effect sizes (Cohen’s d,
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